Naltrexone

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Naltrexone
   1. Pharmacist Assessment Report
   2. Naltrexone: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Naltrexone: Known uses and market status in Australia

Summary

The TxGNN deep-learning model produced no candidate indication with a score of 0.99 or higher for Naltrexone, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	4
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
obesity	licence in another country
overweight	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
monogenic obesity
obesity disorder

Australia Market Information

Licence	Product	Dosage form	Status
8370M	Naltrexone GH	Tablet containing naltrexone hydrochlori	Valid

Safety Considerations

Contraindications flagged in the knowledge graph (these come from graph relationships, not from approved label text, and should be verified against the TGA-approved Product Information):

• Liver conditions: liver failure, acute liver failure, liver disease, hepatitis
• Impaired renal function
• Respiratory conditions: respiratory failure, chronic obstructive pulmonary disease
• Adrenal conditions: Addison disease, adrenal insufficiency, congenital adrenal hyperplasia and related disorders
• Thyroid conditions: hypothyroidism, myxoedema
• Neurological and psychiatric conditions: epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder
• Gastrointestinal and other conditions: pancreatitis, gallbladder disease, chronic diarrhoeal disease, paralytic ileus, benign prostatic hyperplasia, hypotensive disorder

Drug Interactions: The interaction screen returned 100 interactions, of which 20 are shown in the data compiled for this report.

• Major: fentanyl, codeine, dihydrocodeine, tramadol. These opioids are pharmacologically opposed by naltrexone.
• Moderate (examples): ethanol, acetaminophen, ibuprofen, ketorolac, abacavir, lamivudine, zidovudine, abemaciclib, abiraterone, afatinib, acarbose, isotretinoin, acitretin, aldesleukin, alectinib, trastuzumab emtansine.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---